An Ancient Founder GDF2 Variant Potentially Causes Semi‐Dominant Non‐Syndromic Pulmonary Arterial Hypertension
Clinical Genetics · 2026-09 · 110 (3) · 289-298
DOI: 10.1111/cge.70191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, online erschienen am 17.06.2026. Verfasst von Abdullah Aldalaan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Hypertension Program, Lung Health Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Growth Differentiation Factor 2, Founder Effect, Hypertension, Pulmonary, Genetic Predisposition to Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Growth differentiation factor 2 ( GDF2 ), also known as bone morphogenetic protein‐9 ( BMP9 ), is a key member of the transforming growth factor‐beta (TGF‐β) superfamily, playing a pivotal role in pulmonary vascular regulation and remodeling. Dominant variants in GDF2 are known to cause hereditary hemorrhagic telangiectasia type 5 (HHT5), a condition characterized by telangiectases and arteriovenous malformations (AVMs). More recently, recessive variants in GDF2 have been reported to cause pulmonary arterial hypertension (PAH) with or without features of HHT5. In this study, we identified a founder variant in GDF2 that potentially causes semidominant PAH in a cohort of 13 patients ranging in age from pediatric to middle‐aged adults. Careful clinical evaluation revealed a wide range of ages of onset and disease severity. However, lack of HHT manifestations was a consistent clinical feature. Our results lend further support to GDF2 as a bona fide disease gene in the context of non‐syndromic PAH and demonstrate the power of founder variants to reveal the full spectrum of disease variability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary Hypertension Program, Lung Health Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
- Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital, and Research Center, Riyadh, Saudi Arabia.
- Innovation and Research, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
- Genomic Medicine Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
- Lifera Omics, Riyadh, Kingdom of Saudi Arabia.
ORCID-Profile: Seba Nadeef, Ebtissal Khouj, Fowzan S Alkuraya
Zitieren
APA
Aldalaan, A., Nadeef, S., Khouj, E., Alahmadi, F., Aljamal, B., Alturaif, N., Alharbi, N., Abdulwahab, F., Alqahtani, M., Alzubi, F., Abuyousef, O., Hashem, M. O., Zaytoun, H., Alhamoud, H., Alshidi, T., Jaafar, A., Alabdi, L., & Alkuraya, F. S. (2026). An Ancient Founder GDF2 Variant Potentially Causes Semi‐Dominant Non‐Syndromic Pulmonary Arterial Hypertension. Clinical Genetics, 110(3), 289-298. https://doi.org/10.1111/cge.70191
Vancouver
Aldalaan A, Nadeef S, Khouj E, Alahmadi F, Aljamal B, Alturaif N, et al. An Ancient Founder GDF2 Variant Potentially Causes Semi‐Dominant Non‐Syndromic Pulmonary Arterial Hypertension. Clinical Genetics. 2026;110(3):289-298. doi:10.1111/cge.70191
BibTeX
@article{Aldalaan2026,
author = {Aldalaan, Abdullah and Nadeef, Seba and Khouj, Ebtissal and Alahmadi, Fayez and Aljamal, Bayan and Alturaif, Noura and Alharbi, Nadeen and Abdulwahab, Firdous and Alqahtani, Mashael and Alzubi, Fatima and Abuyousef, Omar and Hashem, Mais O and Zaytoun, Hamdiah and Alhamoud, Hanadi and Alshidi, Tarfa and Jaafar, Amal and Alabdi, Lama and Alkuraya, Fowzan S},
title = {An Ancient Founder GDF2 Variant Potentially Causes Semi‐Dominant Non‐Syndromic Pulmonary Arterial Hypertension},
journal = {Clinical Genetics},
year = {2026},
volume = {110},
number = {3},
pages = {289--298},
doi = {10.1111/cge.70191}
}
EUVIMED